[Effects of raloxifene on bone loss and fracture risk in the menopausal woman].
The relevance and efficacy of long-term estrogen therapy is well established, though some undesirable side effects and contraindications persist. Raloxifene, the first selective estrogen receptive modulator (SERM) tested in phase III trials, offers a choice alternative. It increases bone mineral density, lowers serum lipid concentrations and reduces vertebral fractures.
Vignot
E
E
Service de rhumatologie et de pathologie osseuse, Hôpital Edouard-Herriot, Lyon, France.
Meunier
P J
PJ
D000368:Aged; D015519:Bone Density; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010919:Placebos; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000517:prevention & control*
D008055:Lipids; D010919:Placebos; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride